Novartis has issued a Dear Healthcare Professional letter regarding a risk of pure red cell aplasia (PRCA) in patients treated with mycophenolic acid (Myfortic).
Novartis has issued a Dear Healthcare Professional letter regarding a risk of pure red cell aplasia (PRCA) in patients treated with mycophenolic acid (Myfortic).
Cases of PRCA have been reported in patients treated with mycophenolate mofetil (CellCept) in combination with other immunosuppressive agents. Mycophenolate mofetil is converted to mycophenolic acid after oral or intravenous (IV) administration. A warning regarding PRCA in patients treated with mycophenolate mofetil was issued in August 2009.
Mycophenolic acid is approved for use in combination with cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants
Novo Nordisk Terminates Collaboration with Hims & Hers
June 23rd 2025The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
Read More